Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Epithelial immune activation and intracellular invasion by non-typeable Haemophilus influenzae

Brown MA. et al, (2023), Frontiers in Cellular and Infection Microbiology, 13

Editorial: MAIT cells come of age

Corbett AJ. et al, (2023), Frontiers in Immunology, 14

MAIT cells and the microbiome.

Jabeen MF. and Hinks TSC., (2023), Frontiers in immunology, 14

BIO-AST Biologics for chronic severe asthma: a network meta-analysis

Crossingham I. et al, (2022), Cochrane Database of Systematic Reviews, 2022

Azithromycin for mild-to-moderate COVID-19 - Authors' reply.

Hinks TSC. and ATOMIC2 trial authors None., (2021), The Lancet. Respiratory medicine, 9, e100 - e101

Subcutaneous omalizumab for people with asthma

Donovan T. et al, (2021), Cochrane Database of Systematic Reviews, 2021

Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma

Crossingham I. et al, (2021), Cochrane Database of Systematic Reviews

Load More